Dose Escalation Study of Kylo-0603 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

August 16, 2024

Study Completion Date

August 16, 2024

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG

Kylo-0603 capsule

Administrated orally.

DRUG

Placebo

Administrated orally.

Trial Locations (1)

The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Kylonova (Xiamen) Biopharma co., LTD.

INDUSTRY

NCT06365580 - Dose Escalation Study of Kylo-0603 in Healthy Subjects | Biotech Hunter | Biotech Hunter